Hi Bottle 2,
The collaboration is underway. What form that is taking is anyone's guess. Currently it is sharing each other's research and research teams. I assume to work out just how valuable a pooling of resources might be.
The coming together of two lots of research and or expertise (backed by actual financial resources to seriously progress it) may potentially yield some interesting and valuable results.
I am unsure as to why we have had the delay in the naming of the pharma company. Wayne actually first mentioned it back at the AGM and said then he would name them when he could. Please note that anything I say here on this issue is pure speculation.
My personal thought / wish is that the delay is due to the legalities of finalising terms. This may or may not have a financial component. However, when you let someone behind closed doors and into your bunker you have to have a game plan sorted. I suspect they have given them a sneak peek and they have like what they have seen.
So I think there may be some terms around what happens in the event of......... or this......... In other words if we work together and pool our research and talent and we think there is something viable and potentially valuable then if we decide to proceed them these are the future terms and how that would look. We would pay x and you would contribute x and blah blah blah.
So in essence I think these things are always more complicated and take way more time than originally envisaged. I actually think the delay may be a good thing as we iron out and negotiate terms that we can agree on.
All just speculation and I could be very wrong. Just my way of thinking about it. Hopefully we hear something soon. Wayne has not made an ASX announcement as CEO yet and I think April will be a big month for us.
Exciting times ahead.
- Forums
- ASX - By Stock
- BIT BORING
Hi Bottle 2, The collaboration is underway. What form that is...
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.91 | 475 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
1 | 330 | 9.510 |
2 | 1185 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
9.910 | 475 | 2 |
9.990 | 99 | 1 |
10.000 | 250 | 1 |
10.500 | 10005 | 2 |
11.000 | 5000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online